Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In

Quick Launch

Marshall Corson

MARSHALL A. CORSON, MD, FACC, FAHA

Clinical Professor
Attending Physician, ​Regional Heart Center - Edmonds Clinic
Attending Physician, Harborview Medical Center

 
Regional Heart Center - Edmonds (Formerly Alderwood)
Stevens Health Center Building
Box 356006
21701 76th Avenue W., Suite 201
Edmonds, WA 98026

 
 

​EDUCATION AND TRAINING

  • Fellowship, Cardiology, Emory University, Atlanta, GA, 1992
  • Fellowship, Medical Staff Fellow, National Heart, Lung & Blood Institute, National Institutes of Health, Bethesda, MD, 1989
  • Medical Residency, George Washington University, Washington, DC, 1985
  • MD, Baylor College of Medicine, Houston, TX, 1981
  • BA, Brandeis University, Waltham, MA, 1977
 
 

BOARD CERTIFICATION

  • American Board of Internal Medicine, Cardiovascular Diseases, 1993
  • American Board of Internal Medicine, 1986

 

AREAS OF CLINICAL EXPERTISE

  • Cardiovascular Risk Modification
  • General Cardiology and Cardiac Catheterization

CURRENT RESEARCH INTERESTS​​​​​

​​
 

 Selected Publications

 
 
Corson MA "Darapladib: an emerging therapy for atherosclerosis." Therapeutic advances in cardiovascular disease 2010 Aug; 4; 4; 241-8
 
 
Moorman AJ, Corson MA, Goldberger ZD "Right rhythm, right patient, right ventricle." The American journal of medicine 2009 Oct; 122; 10; 913-5
 
 
Corson MA "Phospholipase A2 inhibitors in atherosclerosis: the race is on." Lancet 2009 Feb; 373; 9664; 608-10
 
 
Corson MA "Emerging inflammatory markers for assessing coronary heart disease risk." Current cardiology reports 2009 Nov; 11; 6; 452-9
 
 
Riley RF, Corson MA "Darapladib, a reversible lipoprotein-associated phospholipase A2 inhibitor, for the oral treatment of atherosclerosis and coronary artery disease." IDrugs : the investigational drugs journal 2009 Oct; 12; 10; 648-55
 
 
Corson MA, Jones PH, Davidson MH "Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker." The American journal of cardiology 2008 Jun; 101; 12A; 41F-50F